The Library

The anticancer drug cisplatin can cross-link the interdomain zinc site on human albumin

Tools

Hu, Wenbing, Luo, Qun, Wu, Kui, Li, Xianchan, Wang, Fuyi, Chen, Yi, Ma, Xiaoyan, Wang, Jianping, Liu, Jianan, Xiong, Shaoxiang and Sadler, P. J.. (2011) The anticancer drug cisplatin can cross-link the interdomain zinc site on human albumin. Chemical Communications, Vol.47 (No.21). pp. 6006-6008. ISSN 1359-7345

Preview

Text
WRAP_Sadler_465_Pt-rHA ChemCommun ver4.pdf - Accepted Version
Download (485Kb) | Preview

Official URL: http://dx.doi.org/10.1039/C1CC11627D

Abstract

Cisplatin, cis-[Pt(Cl2(NH3)2], can crosslink residues His67 of domain I and His247 of domain II in human albumin, occupying the major binding site for the essential metal zinc on the protein.

Item Type:	Journal Article
Subjects:	Q Science > QD Chemistry Q Science > QP Physiology R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Faculty of Science > Chemistry
Library of Congress Subject Headings (LCSH):	Cisplatin, Antineoplastic agents, Albumins
Journal or Publication Title:	Chemical Communications
Publisher:	Royal Society of Chemistry
ISSN:	1359-7345
Date:	7 June 2011
Volume:	Vol.47
Number:	No.21
Page Range:	pp. 6006-6008
Identification Number:	10.1039/c1cc11627d
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	Guo jia zi ran ke xue ji jin wei yuan hui (China) [National Natural Science Foundation of China] (NSFC), Zhongguo ke xue yuan [Chinese Academy of Sciences] (CAS), China. Guo jia ke xue ji shu bu [Ministry of Science and Technology of China]
Grant number:	90713020 (NSFC), 20975103 (NSFC), 21020102039 (NSFC)
References:	1 (a) D. Wang and S. J. Lippard, Nat. Rev. Drug Discovery, 2005, 4, 307; (b) R. F. Ozols, Cancer Treat. Rev., 1991, 18, 77; (c) M. A. Jakupec, M. Galanski, V. B. Arion, C. G. Hartinger and B. K. Keppler, Dalton Trans., 2008, 183; (d) B. Lippert, Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, Wiley-VCH, Weinheim, 1999. 2 (a) L. Kelland, Nat. Rev. Cancer, 2007, 7, 573; (b) M. S. Davies, S. J. Berners-Price and T. W. Hambley, Inorg. Chem., 2000, 39, 5603. 3 (a) Y. W. Jung and S. J. Lippard, Chem. Rev., 2007, 107, 1387; (b) S. T. Sullivan, J. S. Saad, F. P. Fanizzi and L. G. Marzilli, J. Am. Chem. Soc., 2002, 124, 1558; (c) Y. Zou, B. Van Houten and N. Farrell, Biochemistry, 1994, 33, 5404; (d) H. Baruah, C. G. Barry and U. Bierbach, Curr. Top. Med. Chem., 2004, 4, 1537. 4 (a) A. R. Timerbaev, C. G. Hartinger, S. S. Aleksenko and B. K. Keppler, Chem. Rev., 2006, 106, 2224; (b) C. Gabbiani, F. Magherini, A. Modesti and L. Messori, Anti-Cancer Agents Med. Chem., 2010, 10, 324; (c) C. G. Hartinger, Y. O. Tsybin, J. Fuchser and P. J. Dyson, Inorg. Chem., 2008, 47, 17; (d) D. Gibson, Dalton Trans., 2009, 10681. 5 (a) R. C. Todd and S. J. Lippard, Metallomics, 2009, 1, 280; (b) A. Eastman, Cancer Cell Mon. Rev., 1990, 2, 275. 6 (a) R. C. Deconti, B. R. Toftness, R. C. Lange and W. A. Creasey, Cancer Res., 1973, 33, 1310; (b) I. Khalaila, A. Bergamo, F. Bussy, G. Sava and P. J. Dyson, Int. J. Oncol., 2006, 29, 261; (c) D. Esteban-Fernandez, M. Montes-Bayon, E. B. Gonzalez, M. M. G. Gomez, M. A. Palacios and A. Sanz-Medel, J. Anal. At. Spectrom., 2008, 23, 378; (d) J. J. Gullo, C. L. Litterst, P. J. Maguire, B. I. Sikic, D. F. Hoth and P. V. Woolley, Cancer Chemother. Pharmacol., 1980, 5, 21. 7 M. Sooriyaarachchi, A. Narendran and J. Gailer, Metallomics, 2011, 3, 49. 8 D. C. Carter and J. X. Ho, Adv. Protein Chem., 1994, 45, 153. 9 (a) C. A. Blindauer, I. Harvey, K. E. Bunyan, A. J. Stewart, D. Sleep, D. J. Harrison, S. Berezenko and P. J. Sadler, J. Biol. Chem., 2009, 284, 23116; (b) J. Lu, A. J. Stewart, P. J. Sadler, T. J. T. Pinheiro and C. A. Blindauer, Biochem. Soc. Trans., 2008, 36, 1317; (c) A. J. Stewart, C. A. Blindauer, S. Berezenko, D. Sleep and P. J. Sadler, Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 3701. 10 A. I. Ivanov, J. Christodoulou, J. A. Parkinson, K. J. Barnham, A. Tucker, J. Woodrow and P. J. Sadler, J. Biol. Chem., 1998, 273, 14721. 11 J. Will, D. A. Wolters and W. S. Sheldrick, ChemMedChem, 2008, 3, 1696. 12 J. D. Sweeney, P. Ziegler, C. Pruet and M. B. Spaulding, Cancer, 1989, 63, 2093. 13 The binding of cisplatin to Cys124 is particularly remarkable because this residue forms a disulfide bond with Cys169 in rHA itself. Although cisplatin-induced disulfide bond cleavage in HA has been described previously (N. Ohta, T. Yotsuyanagi, D. Chen, R. Ono, S. Ito and K. Ikeda, Int. J. Pharm., 1992, 85, 39), it has not been identified and localized in albumin before. The biological and pharmacological implications of the cisplatin-induced cleavage of this disulfide bond will be discussed elsewhere. 14 The zinc indicator 4-(2-pyridylazo)resorcinol (PAR) was used to determine the content of zinc bound to rHA (for details see the Experimental section in ESIw). 15 T. J. Peters, All About Albumin: Biochemistry, Genetics, and Medical Applications, Academic Press, 1995. 16 (a) A. Gerl and R. Schierl, Acta Oncol., 2000, 39, 519; (b) E. Moreno-Gordaliza, B. Canas, M. A. Palacios and M. M. Gomez-Gomez, Analyst, 2010, 135, 1288. 17 R. P. Sharma, Pharmacol. Res. Commun., 1985, 17, 197. 18 (a) D. Hagrman, J. Goodisman, J. C. Dabrowiak and A. K. Souid, Drug Metab. Dispos., 2003, 31, 916; (b) M. Knipp, A. V. Karotki, S. Chesnov, G. Natile, P. J. Sadler, V. Brabec and M. Vasak, J. Med. Chem., 2007, 50, 4075; (c) G. X. Zhang, W. B. Hu, Z. F. Du, S. Lv, W. Zheng, Q. Luo, X. C. Li, K. Wu, Y. M. Han and F. Y. Wang, Int. J. Mass Spectrom., 2011, DOI: 10.1016/j.ijms.2010.12.003. 19 Q. A. de Paula, J. B. Mangrum and N. P. Farrell, J. Inorg. Biochem., 2009, 103, 1347. 20 (a) L. Maurmann and R. N. Bose, Dalton Trans., 2010, 39, 7968–7979; (b) T. J. Kelley, S. Moghaddas, R. Bose and S. Basu, Cancer Biochem. Biophys., 1993, 13, 135. 21 S. Curry, H. Mandelkow, P. Brick and N. Franks, Nat. Struct. Biol., 1998, 5, 827.
URI:	http://wrap.warwick.ac.uk/id/eprint/40343